RBX 7455

Drug Profile

RBX 7455

Alternative Names: RBX-7455

Latest Information Update: 11 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rebiotix
  • Developer Mayo Clinic; Rebiotix
  • Class Antibacterials; Bacteria; Probiotics
  • Mechanism of Action Gastrointestinal microbiome modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Clostridium-difficile-infections

Most Recent Events

  • 02 Jun 2018 Interim efficacy and adverse events data from the phase I trial in Clostridium difficile infections presented at the Digestive Disease Week (DDW-2018)
  • 09 Jan 2018 Rebiotix plans a phase II trial for Clostridium difficile infections in USA in 2018
  • 09 Jan 2018 Rebiotix announces intention to submit IND to US FDA in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top